Physician profile
Mark T Friedman
NPI 1548269558
$3,243.51
in general payments reported to CMS, 2019-2025
15 companies · $246 in 2025
The $246 reported for 2025 was more than what 81% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2021: $1,170 · 2022: $404 · 2023: $455 · 2024: $520 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cerus Corporation | $750.00 | 2021 | |
| Gilead Sciences, INC. | $316.00 | 2019-2022 | |
| Esperion Therapeutics, INC. | $299.82 | 2021 | |
| Novo Nordisk INC | $250.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.99 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.94 | 2023-2025 | Jardiance |
| Haemonetics Corporation | $241.77 | 2023-2024 | Bloodtrack, Teg6s Hemostasis System |
| Werfen USA LLC | $175.08 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $150.00 | 2024 | Voquezna |
| Amgen INC. | $125.00 | 2024 | Repatha |
| Alcresta Therapeutics, INC. | $124.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.36 | 2021 | |
| Hemosonics LLC | $76.01 | 2025 | Qunatra Qplus System, Quantra Qplus System |
| Shire North American Group INC | $73.44 | 2019 | |
| Genzyme Corporation | $45.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.